Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

Fig. 4

Remibrutinib inhibits RatMOG EAE. a Dosing of 30 mg/kg p.o. b.i.d. remibrutinib significantly reduced RatMOG EAE scores from day 12 onward (p < 0.05). Group sizes n = 10 per treatment. Statistical significance determined using Kruskal–Wallis with Dunn’s test (means with standard errors). b Trough BTK occupancy was assessed 16 h after the last dose in spleen, blood and brain homogenate (p < 0.001). Statistical significance determined by ANOVA and Sidak’s test (LOU  remibrutinib, VEH vehicle)

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094